O ver a decade ago, EBM was defined as the conscientious and judicious use of current best evidence from clinical care research in the management of individual patients. 1 Since then, EBM has become the darling and the devil of medicine. Proponents have rated it as one of the greatest advances in medicine, 2 and its virtues are extolled in the lay press. 3 Critics, on the other hand, have raised various concerns, which include the charge that EBM inappropriately weights types of evidence (such as RCTs, compared with cohort studies) 4 and the charge that EBM is overly formulaic and diminishes the role of the physician 5 -even referring to the structure of EBM as "fascist." 6 Putting aside the rhetoric, what are some of the challenges faced by physicians who would like to believe they practise EBM? In this issue, Dr Dennis Seow and Dr Serge Gauthier 7 review the pharmacotherapy of AD with a focus on cognitive, functional, and disease-modifying therapies, while Dr Krista Lanctôt and I review the pharmacotherapy of neuropsychiatric symptoms of AD. 8 AD therapeutics offers a unique medium in which to explore the EBM challenges, given the richness of the datasets highlighted in these reviews.
"Duelling Metas"-The Challenge of Discordant Reviews
The first challenge facing the clinician occurs in the context of an "embarrassment of riches"-where lots of data exist. At the top of the EBM food chain sits the systematic review of RCTs. For the practising clinician, these reviews offer a one-stop shop that can theoretically summarize the available studies, rate their quality, and statistically combine their data, weighting studies by sample size, variability, and (or) quality to arrive at conclusions about efficacy and safety-but what is an EBM clinician to do when systematic reviews arrive at opposite conclusions? There have been multiple systematic reviews of the cholinesterase inhibitors for the treatment of mild-to-moderate AD. [9] [10] [11] [12] [13] Although most have suggested benefit, an influential review by Kaduszkiewicz et al, 13 published in the British Medical Journal, questioned the scientific basis for cholinesterase inhibitor use, given methodological flaws in the published studies and small clinical benefits. In cases like this, there are tools available to rate the quality of systematic reviews 14 and even to interpret discordant reviews. 15 Unfortunately, without a thorough understanding of the methodology of the pivotal trials and (or) the review of a large number of other systematic reviews, it would be extremely challenging for front-line clinicians to reach firm conclusions. Kaduszkiewicz et al, for example, did not statistically combine data from the pivotal RCTs. Had they done so, they would have discovered that these studies demonstrated remarkably consistent, statistically significant results, whether the outcome of interest was cognition or clinical global impression-the 2 primary outcomes mandated by the health regulatory agencies for cognitive-enhancer approval. Further, these studies demonstrate for the most part the holy grail of clinical pharmacology-a dose-response relation.
Two approaches have been used to deal with questions regarding the clinical meaningfulness of a modest improvement in cognition and global measures. For example, in one metaanalysis it was noted that the NNT for one additional patient to demonstrate a global response to cholinesterase inhibitors was 12. 9 This compares favourably with the treatment of other chronic medical conditions such as hypertension, where NNTs for 5 years of treatment to prevent one major cardiovascular or cerebrovascular event range from 29 to 86. Another approach to determine clinical meaningfulness is to calculate the effect size of the RCTs. Effect size refers to a group of statistical methods that measure the magnitude of a treatment effect, taking into account the treatment group differences and the observed variance around the outcome measures. In another metaanalysis of the cholinesterase inhibitor RCTs, effect sizes were small to moderate and reasonably consistent, and a dose-response relation was evident. 11 Thus it appears that the EBM clinician can be reasonably sure that cholinesterase inhibitors provide not only statistically significant but also clinically significant benefits. However, even after convincing himself or herself of the statistical and clinical significance of these studies, other questions might plague the clinician. Are these clinical benefits "good enough" or cost-effective? There is vigorous debate about this. Do the patients in these trials actually resemble the patient you intend to treat? There is some evidence that this is not the case because more than one-half the patients treated with these drugs in community settings would likely meet exclusion criteria for the RCTs. 16 Are there clinical characteristics that might predict which individual patient is more or less likely to respond? This is largely unknown. 17 How long should treatment persist? Most of the RCTs were of 3 to 6 months' duration, with only a few lasting for 1 year. Are there meaningful differences between the 3 available drugs? The studies of the existing head-to-head trials are seriously flawed. 18 These questions lead to the second important challenge facing EBM clinicians: What does one do when there is insufficient evidence to support treatment recommendations?
"Take It on Faith"-The Challenge of Insufficient Data
It is almost universally recommended by clinical practice guidelines that the management of neuropsychiatric symptoms of dementia should begin with nonpharmacologic approaches. But what is the evidence supporting nonpharmacologic interventions? There are numerous metaanalyses of published trials of nonpharmacologic approaches that include hundreds of trials. [19] [20] [21] [22] [23] The quality of the vast majority of these trials is poor, and many are excluded from the systematic reviews because of such glaring limitations as poorly characterized study participants, inadequate data collection, lack of valid and reliable pre-and postintervention measurements, and insufficient statistical analysis. 21 Another omission that appears to have eluded the authors of these reviews is a lack of appropriate harms reporting. Although it is often assumed that nonpharmacologic interventions are safe, these studies should be forced to report adverse events with the same rigour demanded of pharmacotherapy RCTs. These reviews invariably conclude that, although nonpharmacologic interventions are promising, more high-quality studies are required and also that there is insufficient evidence to recommend the use of many of the individual interventions. As noted by Herrmann and Lanctôt, 8 if these interventions required the approval of health regulatory agencies, none would be approved for use according to current criteria for approving pharmacotherapies. Does this mean that the EBM clinician should refrain from suggesting nonpharmacologic therapies? Certainly not. As has been persuasively argued by Cohen-Mansfield and Mintzer, 24 there are numerous reasons for the limitations of the existing research, as well as barriers to using these approaches in clinical practice. Because the theoretical underpinning of nonpharmacologic treatments is to address the unmet needs of patients with dementia, these approaches therefore form the basis of what these authors refer to as "humanitarian" and "structured good care." Thus, even in the absence of good evidence, the EBM clinician might rely on this ethical approach and recommend nonpharmacologic therapies. However, what about the situation where good evidence exists but is unavailable to most clinicians? This represents the third, and potentially most serious, challenge facing the EBM clinician.
"The File Drawer Problem"-The Challenge of Unpublished Data
The atypical antipsychotics are used frequently for the treatment of agitation, aggression, and psychosis in dementia, on the basis of evidence from large, published, high-quality RCTs. 8 Beginning in 2002, however, with the first safety warning for risperidone and an increased risk of cerebrovascular adverse events, a shocking truth was revealed-there existed a large number of RCTs that had never been published. For example, a metaanalysis of cerebrovascular adverse events in RCTs of olanzapine and risperidone treatment in dementia patients reviewed 11 completed studies. 25 Of this total, 6 were unpublished. Similarly, a metaanalysis of mortality in RCTs of atypical antipsychotic use in dementia treatment reviewed a total of 15 trials, 9 of which were unpublished. 26 If so many of these trials are unpublished, and given that most systematic reviews and metaanalyses rely on published data, how can EBM clinicians determine whether the efficacy of these drugs outweighs their risks, or even whether they are effective at all? Skeptics might conclude that these trials were not published because they were all negative studies. If so, they might certainly tip the balance between risks and benefits. There are no simple solutions to this challenge, although the use of funnel plots in metaanalytic studies can provide some idea of how many unpublished negative studies would be required to affect the outcome of the metaanalysis. A more definitive solution would be to require all pharmaceutical companies to make data available to researchers regardless of whether the study is published or not. The requirements for clinical trial registration represent a step in the right direction, but they do not include the requirement to publicize results. 27 One solution would be to legislate that pharmaceutical companies provide a minimum of outcomes (for example, the primary outcome NNT number needed to treat measure) and detailed harms reporting (for example, conforming to the Consolidated Standards of Reporting Trials guidelines) 28 within 1 year of trial completion. This solution would also have to be approved by scientific journals so that potential authors would not be punished for "previously published data."
Summary
The practice of EBM has evolved since it was first defined. Even the most ardent EBM proponents have recognized the need to modify the EBM approach and now include elements such as the patient's clinical state and circumstances, the patient's preferences and actions, and the physician's clinical expertise, as well as the research evidence. 29 Part of the clinical expertise required in this model is the ability to interpret and apply the research evidence. This editorial has highlighted some of the challenges faced by clinicians who would treat AD with an EBM approach. It suggests that, without a sophisticated understanding of the primary research studies, it might be hazardous to rely on a single RCT, or even on a systematic review, for treatment recommendations. If expert assistance is required, one solution might be to rely on clinical practice guidelines developed through a consensus approach.
Although clinical practice guidelines have also been criticized, 30 they appear to provide the best blend of EBM and expert opinion. The results of the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia will be published shortly. Hopefully, this will provide helpful guidance for Canadian clinicians and their AD patients.
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